GSK sees positive results on asthma, COPD drug expected to succeed Advair – MedCity News

GSK sees positive results on asthma, COPD drug expected to succeed Advair
MedCity News
The results boost the compound's prospects as a successor to GSK's blockbuster asthma and COPD drug Advair, whose patents have expired. London-based GSK, which maintains its US headquarters in Research Triangle Park, North Carolina, and drug partner
GSK gets good news on asthma drugTriangle Business Journal
Glaxo Drug Gets Positive Trial ResultsWall Street Journal
Theravance, Glaxo Lung Drug Passes Two Pivotal Trials; Two More to GoXconomy
MarketWatch –Forbes –stv.tv
all 36 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *